CY1118436T1 - Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου - Google Patents

Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου

Info

Publication number
CY1118436T1
CY1118436T1 CY20161101244T CY161101244T CY1118436T1 CY 1118436 T1 CY1118436 T1 CY 1118436T1 CY 20161101244 T CY20161101244 T CY 20161101244T CY 161101244 T CY161101244 T CY 161101244T CY 1118436 T1 CY1118436 T1 CY 1118436T1
Authority
CY
Cyprus
Prior art keywords
compositions containing
weight
replaced
carbon atoms
alkyl group
Prior art date
Application number
CY20161101244T
Other languages
English (en)
Inventor
Laura Rabinovich-Guilatt
Gregory Lambert
Frederic Lallemand
Betty Philips
Original Assignee
Santen Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/494,493 external-priority patent/US20080026013A1/en
Priority claimed from EP06291236.5A external-priority patent/EP1891939B1/en
Application filed by Santen Sas filed Critical Santen Sas
Publication of CY1118436T1 publication Critical patent/CY1118436T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A61L12/143—Quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/62—Quaternary ammonium compounds
    • C07C211/63—Quaternary ammonium compounds having quaternised nitrogen atoms bound to acyclic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Αυτή η εφεύρεση σχετίζεται με συνθέσεις που περιέχουν ενώσεις τεταρτοταγούς αμμωνίου στις οποίες το άτομο αζώτου είναι αντικατεστημένο με τουλάχιστον μία ομάδα αλκυλίου (alkyl) που έχει τουλάχιστον 12 άτομα άνθρακα, που χαρακτηρίζεται από το ότι η εν λόγω σύνθεση περιλαμβάνει τουλάχιστον 20% σε βάρος ανά βάρος της ολικής σύνθεσης, αλογονίδια αμμωνίου στα οποία το άτομο αζώτου είναι αντικατεστημένο με τουλάχιστον μία ομάδα αλκυλίου (alkyl) που έχει τουλάχιστον 14 άτομα άνθρακα και περισσότερα από 5%, κατά προτίμηση περισσότερο από 7% σε βάρος ανά βάρος της ολικής σύνθεσης, αλογονίδια αμμωνίου στα οποία το άτομο αζώτου είναι αντικατεστημένο με τουλάχιστον μία ομάδα αλκυλίου (alkyl) που έχει τουλάχιστον 16 άτομα άνθρακα. Αυτή η εφεύρεση σχετίζεται επίσης με οφθαλμικά γαλακτώματα λαδιού μέσα σε νερό που περιέχουν τέτοιες συνθέσεις που είναι χρήσιμες για την φροντίδα των ματιών ή για την θεραπεία παθήσεων των ματιών.
CY20161101244T 2006-07-28 2016-12-02 Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου CY1118436T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11/494,493 US20080026013A1 (en) 2006-07-28 2006-07-28 Compositions containing quaternary ammonium compounds
EP06291236.5A EP1891939B1 (en) 2006-07-28 2006-07-28 Compositions containing quaternary ammonium compounds
EP07112097 2007-07-09
PCT/IB2007/053441 WO2008035246A2 (en) 2006-07-28 2007-07-10 Compositions containing quaternary ammonium compounds
EP07787998.9A EP2049079B1 (en) 2006-07-28 2007-07-27 Compositions containing quaternary ammonium compounds
PCT/EP2007/057784 WO2008012367A2 (en) 2006-07-28 2007-07-27 Compositions containing quaternary ammonium compounds

Publications (1)

Publication Number Publication Date
CY1118436T1 true CY1118436T1 (el) 2017-06-28

Family

ID=65014357

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20161100773T CY1118148T1 (el) 2006-07-28 2016-08-05 Συνθεση που περιεχει ενωσεις τεταρτοταγους αμμωνιου
CY20161101244T CY1118436T1 (el) 2006-07-28 2016-12-02 Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου
CY2017007C CY2017007I2 (el) 2006-07-28 2017-02-22 Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161100773T CY1118148T1 (el) 2006-07-28 2016-08-05 Συνθεση που περιεχει ενωσεις τεταρτοταγους αμμωνιου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2017007C CY2017007I2 (el) 2006-07-28 2017-02-22 Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου

Country Status (18)

Country Link
US (7) US7973081B2 (el)
EP (2) EP2404593B1 (el)
JP (1) JP5441058B2 (el)
KR (2) KR101507097B1 (el)
AU (1) AU2007278141B2 (el)
CA (1) CA2659322C (el)
CY (3) CY1118148T1 (el)
DK (2) DK2404593T3 (el)
ES (2) ES2586381T3 (el)
HK (1) HK1165993A1 (el)
HU (2) HUE029987T2 (el)
IL (2) IL196740A (el)
LT (2) LT2049079T (el)
LU (1) LUC00006I2 (el)
PL (2) PL2404593T3 (el)
PT (2) PT2404593T (el)
SI (2) SI2049079T1 (el)
WO (2) WO2008035246A2 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2916636B1 (fr) * 2007-05-29 2009-09-04 Octalia Technologies Vehicule sous forme d'une emulsion huile-dans-eau notamment destine a une utilisation ophtalmique ou dermocosmetique
AU2009260572B2 (en) * 2008-05-28 2015-07-23 Alcon Research, Ltd. Self-preserved emulsions
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2228057A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Cationic oil-in-water emulsions containing prostaglandins and uses thereof
MX2011011619A (es) 2009-05-01 2012-02-28 Signal Invest And Man Co Composicion antimicrobiana hidratante.
KR101778316B1 (ko) 2009-06-05 2017-09-13 알러간, 인코포레이티드 인공 눈물 및 치료학적 용도
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
WO2013098841A1 (en) * 2011-10-31 2013-07-04 Fdc Limited Nanodispersion of poorly water soluble drug(s)
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PL2787968T3 (pl) * 2011-12-07 2020-08-24 Allergan, Inc. Wydajne dostarczanie lipidów do ludzkiego filmu łzowego z użyciem wrażliwego na sól układu emulsyjnego
EP2664329A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Ophthalmologisches Vehikelsystem
US20170119885A1 (en) * 2014-04-28 2017-05-04 Hampton Technologies Ophthalmic compositions and methods for treating eyes
US20160074178A1 (en) * 2014-09-17 2016-03-17 Van Phillips METHODS FOR PREPARING PRECISELY FITTED CASTS for PROSTHETICS
EP3011959A1 (en) * 2014-10-23 2016-04-27 Santen SAS Quaternary ammonium compound for use as an inhibitor of protein kinase C alpha
AU2015353701B2 (en) 2014-11-25 2021-03-25 Allergan, Inc. Stabilized omega-3 ophthalmic compositions
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
RS58292B1 (sr) * 2016-07-07 2019-03-29 Salvat Lab Sa Oftalmološka kompozicija sa ricinusovim uljem i srednjim lancem triglicerida
EP3970692A1 (en) * 2020-09-18 2022-03-23 Omnivision GmbH Lipid-based ophthalmic composition for the treatment of dry eye
EP4241761A1 (en) 2020-11-09 2023-09-13 Scai Therapeutics Co., Ltd. Solid cyclosporin a and dispersion composition comprising same
US11471475B1 (en) 2022-03-08 2022-10-18 Ralph P. Stone Ophthalmic suspension vehicles and related methods for pharmaceutical ingredient delivery
WO2024069490A1 (en) * 2022-09-28 2024-04-04 Polaroid Ip B.V. Antimicrobial coating compositions

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB633175A (en) * 1946-09-03 1949-12-12 Parke Davis & Co Antibiotic preparations and process for obtaining the same
USB724600I5 (el) * 1968-04-26
AU499860B2 (en) 1975-04-24 1979-05-03 Honda Giken Kogyo Kabushiki Kaisha Deflector plate to equalise fuel distribution in induction gas flow
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
FR2648462B1 (fr) 1989-06-15 1994-01-28 Oreal Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede
JPH05116286A (ja) 1991-10-25 1993-05-14 Matsushita Electric Ind Co Ltd インク吐出装置
IL101241A (en) 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
WO1994005298A1 (en) 1992-08-28 1994-03-17 Pharmos Corporation Submicron emulsions as ocular drug delivery vehicles
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
US5951988A (en) * 1993-03-30 1999-09-14 University Of Saskatchewan Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
DE69411816T2 (de) 1993-06-25 1998-12-03 Alcon Cusi S A Neue Verwendung von polymeren Membranen zum Ausgeben von pharmazeutischen Lösungen, die quarternäre, als Konserviermittel dienende Ammoniumverbindungen enthalten und entsprechender Dosierbehälter
EP0642782B1 (en) * 1993-08-30 2002-11-06 Unilever Plc Shampoo-conditioner composition
EP0760650B1 (en) 1994-05-20 2002-07-31 Novavax, Inc. Antimicrobial oil-in-water emulsions
US5547990A (en) * 1994-05-20 1996-08-20 Lonza, Inc. Disinfectants and sanitizers with reduced eye irritation potential
US5435998A (en) * 1994-08-03 1995-07-25 Abelson; Mark B. Treatment of low-tension glaucoma by topical administration of calcium channel blocking agents
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5767153A (en) 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
TW446563B (en) * 1996-01-16 2001-07-21 Colgate Palmolive Co Low static conditioning shampoo
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
EP0878197B1 (en) 1997-05-14 2002-08-21 Senju Pharmaceutical Co., Ltd. Compositions containing difluprednate
US20020169138A1 (en) * 1997-10-24 2002-11-14 Southern Research Institute Delivery vehicles for bioactive agents and uses thereof
WO1999051763A1 (en) 1998-04-02 1999-10-14 The Schepens Eye Research Institute, Inc. Corneal organ culture system for chemical toxicity tests of consumer products
FR2780879B1 (fr) * 1998-07-09 2002-09-20 Oreal Composition cosmetique photoprotectrice contenant un tensio-actif anionique, un compose filtrant le rayonnement ultraviolet et un compose cationique ou zwitterionique amphiphile et son utilisation
WO2000018316A2 (en) * 1998-09-25 2000-04-06 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
US6030789A (en) 1999-03-10 2000-02-29 The Gillette Company Human conjunctival epithelial cell lines with an extended life span
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
JP2003510263A (ja) * 1999-09-24 2003-03-18 アルコン，インコーポレイテッド シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物
EP1142566B1 (fr) 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
US20030017181A1 (en) * 2001-05-31 2003-01-23 Rood Gloria A. Dermatological compositions and methods
AU2002367976B2 (en) 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
DE60142187D1 (de) 2001-11-01 2010-07-01 Yissum Res Dev Co Verfahren und zusammensetzung zur behandlung von trockenen augen
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
WO2003080027A1 (en) 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP5382972B2 (ja) 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物
US20050175651A1 (en) 2004-01-09 2005-08-11 L'oreal Aqueous dispersion of nanocapsules with an oily core
US20050158349A1 (en) 2004-01-20 2005-07-21 Jampani Hanuman B. Two-phase compositions containing alcohol
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
ES2314354T3 (es) * 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
AU2005304034B2 (en) * 2004-11-09 2012-02-16 Santen Sas Ophthalmic emulsions containing an immunosuppressive agent
US20070231406A1 (en) 2006-01-30 2007-10-04 Bucalo Louis R Use of gallium to treat biofilm-associated infections
US20080026013A1 (en) 2006-07-28 2008-01-31 Laura Rabinovich-Guilatt Compositions containing quaternary ammonium compounds
US20090018057A1 (en) * 2007-07-09 2009-01-15 Gregory Lambert OIL IN WATER EMULSION COMPRISING NSAIDs AND QUATERNARY AMMONIUM HALIDES

Also Published As

Publication number Publication date
US20130337019A1 (en) 2013-12-19
US9956289B2 (en) 2018-05-01
EP2049079A2 (en) 2009-04-22
CA2659322A1 (en) 2008-01-31
EP2404593A1 (en) 2012-01-11
KR101507465B1 (ko) 2015-03-31
IL241753B (en) 2018-03-29
US20160082107A1 (en) 2016-03-24
IL196740A0 (en) 2009-11-18
DK2049079T3 (da) 2017-01-02
LTC2049079I2 (lt) 2019-12-27
AU2007278141B2 (en) 2014-01-16
US8524779B2 (en) 2013-09-03
LUC00006I1 (el) 2017-02-28
EP2049079B1 (en) 2016-09-07
JP2009544667A (ja) 2009-12-17
US10842873B2 (en) 2020-11-24
WO2008012367A2 (en) 2008-01-31
CY2017007I1 (el) 2017-06-28
WO2008012367A3 (en) 2008-05-29
ES2586381T3 (es) 2016-10-14
US9220694B2 (en) 2015-12-29
PL2404593T3 (pl) 2016-11-30
LTPA2017003I1 (lt) 2017-03-10
KR20090047496A (ko) 2009-05-12
PL2049079T3 (pl) 2017-03-31
AU2007278141A1 (en) 2008-01-31
ES2606467T3 (es) 2017-03-24
IL196740A (en) 2015-10-29
SI2049079T1 (sl) 2017-03-31
US20190022231A1 (en) 2019-01-24
IL241753A0 (en) 2015-11-30
US20230181738A1 (en) 2023-06-15
HK1165993A1 (zh) 2012-10-19
PT2404593T (pt) 2016-08-16
EP2404593B1 (en) 2016-05-11
WO2008035246A2 (en) 2008-03-27
US20210038721A1 (en) 2021-02-11
SI2404593T1 (sl) 2016-11-30
KR20140041845A (ko) 2014-04-04
CA2659322C (en) 2014-07-15
US20110201689A1 (en) 2011-08-18
US20080026991A1 (en) 2008-01-31
DK2404593T3 (en) 2016-08-29
CY2017007I2 (el) 2017-06-28
HUE029987T2 (en) 2017-04-28
JP5441058B2 (ja) 2014-03-12
LT2049079T (lt) 2016-12-12
WO2008035246A3 (en) 2008-06-26
KR101507097B1 (ko) 2015-03-31
US7973081B2 (en) 2011-07-05
CY1118148T1 (el) 2017-06-28
PT2049079T (pt) 2016-12-09
US11612658B2 (en) 2023-03-28
HUE030841T2 (en) 2017-06-28
US20200000924A9 (en) 2020-01-02
LUC00006I2 (el) 2017-05-02

Similar Documents

Publication Publication Date Title
CY1118436T1 (el) Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου
CY1118096T1 (el) Ρυθμιστες υποδοχεα οπιοειδους
CY1114457T1 (el) Συνθεσεις που περιεχουν ενωσεις τεταρτοταγους αμμωνιου (quaternary ammonium)
EA202193338A1 (ru) Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина
CY1107871T1 (el) Παραγωγα πυριμιδινης και η χρηση τους ως ρυθμιστων cb2
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
CY1114091T1 (el) ΠΑΡΑΓΟΝΤΕΣ ΓΙΑ ΠΡΟΛΗΨΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΔΙΑΤΑΡΑΧΩΝ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΟΥΝ ΔΙΑΦΟΡΟΠΟΙΗΣΗ ΤΩΝ ΥΠΟΔΟΧΕΩΝ RyR
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CY1110965T1 (el) Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
EA201490489A1 (ru) Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7
CY1121898T1 (el) Ενωσεις αμιδιου ως αγωνιστες tου υποδοχεα 5-ht4
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
CY1121865T1 (el) Οφθαλμολογικες συνθεσεις και η χρηση τους
CY1110343T1 (el) 2-(πυριδιν-2-υλο)-πυριμιδινες και η χρησιμοποιηση του για την καταπολεμηση επιζημιων μυκητων
CY1113257T1 (el) Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων
CY1116452T1 (el) Θετικοι αλλοστερικοι ρυθμιστες μ1 υποδοχεα του τυπου πυρανυλ αρυλ μεθυλ βενζοκιναζολινονης
CY1109214T1 (el) Μειγματα μυκητοκτονου που βασιζονται σε παραγωγα καρβαμικου και εντομοκτονα
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3